RhoVac ApS
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Subsidiary
- Established
- 2008-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.rhovac.com
Clinical Trials
8
Active:7
Completed:1
Trial Phases
2 Phases
Phase 1:7
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Phase 1
7 (87.5%)Phase 2
1 (12.5%)Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer
Phase 2
Active, not recruiting
- Conditions
- Prostate Cancer Recurrent
- First Posted Date
- 2019-10-03
- Last Posted Date
- 2021-09-28
- Lead Sponsor
- RhoVac APS
- Target Recruit Count
- 180
- Registration Number
- NCT04114825
- Locations
- 🇺🇸
Tampa Bay Medical Research, Clearwater, Florida, United States
🇺🇸Chesapeake Urology Research Associates, Towson, Maryland, United States
🇺🇸GU Research Network/Urology Cancer Center, Omaha, Nebraska, United States
RV001V, a RhoC Anticancer Vaccine, Against Metastasis From Solid Tumours
Phase 1
Completed
- Conditions
- Prostate Cancer
- First Posted Date
- 2017-06-27
- Last Posted Date
- 2020-06-09
- Lead Sponsor
- RhoVac APS
- Target Recruit Count
- 22
- Registration Number
- NCT03199872
- Locations
- 🇩🇰
Rigshospitalet, Copenhagen, Denmark
News
No news found